280 related articles for article (PubMed ID: 29992502)
1. DNA methylation alterations as therapeutic prospects in thyroid cancer.
Zhang K; Li C; Liu J; Tang X; Li Z
J Endocrinol Invest; 2019 Apr; 42(4):363-370. PubMed ID: 29992502
[TBL] [Abstract][Full Text] [Related]
2. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
4. An update on molecular biology of thyroid cancers.
Omur O; Baran Y
Crit Rev Oncol Hematol; 2014 Jun; 90(3):233-52. PubMed ID: 24405857
[TBL] [Abstract][Full Text] [Related]
5. New Therapies for Advanced Thyroid Cancer.
Laha D; Nilubol N; Boufraqech M
Front Endocrinol (Lausanne); 2020; 11():82. PubMed ID: 32528402
[TBL] [Abstract][Full Text] [Related]
6. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside.
Abdel-Rahman O
Crit Rev Oncol Hematol; 2015 Apr; 94(1):45-54. PubMed ID: 25560732
[TBL] [Abstract][Full Text] [Related]
7. Epigenetics of thyroid cancer and novel therapeutic targets.
Russo D; Damante G; Puxeddu E; Durante C; Filetti S
J Mol Endocrinol; 2011 Jun; 46(3):R73-81. PubMed ID: 21325372
[TBL] [Abstract][Full Text] [Related]
8. Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells.
Massimino M; Tirrò E; Stella S; Frasca F; Vella V; Sciacca L; Pennisi MS; Vitale SR; Puma A; Romano C; Manzella L
Anticancer Res; 2018 Dec; 38(12):6653-6662. PubMed ID: 30504373
[TBL] [Abstract][Full Text] [Related]
9. Autophagy and thyroid carcinogenesis: genetic and epigenetic links.
Morani F; Titone R; Pagano L; Galetto A; Alabiso O; Aimaretti G; Isidoro C
Endocr Relat Cancer; 2014 Feb; 21(1):R13-29. PubMed ID: 24163390
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation in thyroid cancer.
Zafon C; Gil J; Pérez-González B; Jordà M
Endocr Relat Cancer; 2019 Jul; 26(7):R415-R439. PubMed ID: 31035251
[TBL] [Abstract][Full Text] [Related]
11. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
12. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.
Kojic KL; Kojic SL; Wiseman SM
Expert Rev Anticancer Ther; 2012 Mar; 12(3):345-57. PubMed ID: 22369326
[TBL] [Abstract][Full Text] [Related]
13. Precision Medicine Approach to Anaplastic Thyroid Cancer: Advances in Targeted Drug Therapy Based on Specific Signaling Pathways.
Samimi H; Fallah P; Naderi Sohi A; Tavakoli R; Naderi M; Soleimani M; Larijani B; Haghpanah V
Acta Med Iran; 2017 Mar; 55(3):200-208. PubMed ID: 28282720
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy: a new hope for thyroid carcinomas.
Perri F; Pezzullo L; Chiofalo MG; Lastoria S; Di Gennaro F; Scarpati GD; Caponigro F
Crit Rev Oncol Hematol; 2015 Apr; 94(1):55-63. PubMed ID: 25465739
[TBL] [Abstract][Full Text] [Related]
15. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
Bible KC; Ryder M
Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
[TBL] [Abstract][Full Text] [Related]
16. The epigenetic landscape of differentiated thyroid cancer.
Asa SL; Ezzat S
Mol Cell Endocrinol; 2018 Jul; 469():3-10. PubMed ID: 28711609
[TBL] [Abstract][Full Text] [Related]
17. New Insights in Thyroid Cancer and p53 Family Proteins.
Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
[TBL] [Abstract][Full Text] [Related]
18. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum GE; Morkos M; Kim B; Arafat W
Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
[TBL] [Abstract][Full Text] [Related]
19. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
20. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
